Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents
Molly Brewer(UConn Health), Robert C. Bast(The University of Texas MD Anderson Cancer Center), Urs Utzinger(The University of Texas at Austin), E. Neely Atkinson(The University of Texas Health Science Center at Houston), Rebecca Richards‐Kortum(Rice University), Yang Li(Capital Medical University), William C. Satterfield(The University of Texas MD Anderson Cancer Center), Nelly Auersperg(University of Central Florida), Michele Follen
Cited by 35
Related Papers
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology*
|Endocrine Reviews|2001|999